Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone

Ugo De Giorgi; Paola Caroli; Salvatore L. Burgio; Cecilia Menna; Vincenza Conteduca; Emanuela Bianchi; Francesca Fabbri; Elisa Carretta; Dino Amadori; Giovanni Paganelli; Federica Matteucci

doi:10.18632/oncotarget.2558

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone

Ugo De Giorgi _, Paola Caroli, Salvatore L. Burgio, Cecilia Menna, Vincenza Conteduca, Emanuela Bianchi, Francesca Fabbri, Elisa Carretta, Dino Amadori, Giovanni Paganelli and Federica Matteucci

PDF | HTML | How to cite

Oncotarget. 2014; 5:12448-12458. https://doi.org/10.18632/oncotarget.2558

Metrics: PDF 2274 views | HTML 3951 views | ?

Abstract

Ugo De Giorgi1, Paola Caroli2, Salvatore L. Burgio1, Cecilia Menna1, Vincenza Conteduca1, Emanuela Bianchi1, Francesca Fabbri3, Elisa Carretta3, Dino Amadori1, Giovanni Paganelli2, Federica Matteucci2

1Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) IRCCS, Meldola, Italy

2Department of Nuclear Medicine, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) IRCCS, Meldola, Italy

3Biostatistics and Clinical Trials Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) IRCCS, Meldola, Italy

Correspondence to:

Ugo De Giorgi, e-mail: [email protected]

Keywords: Abiraterone, Castration-resistant prostate cancer, 18F-fluorocholine positron emission tomography, PSA, Bone flare

Received: August 13, 2014 Accepted: October 01, 2014 Published: October 11, 2014

ABSTRACT

Objective: We investigated the role of 18F-fluorocholine positron emission tomography/computed tomography (FCH-PET/CT) in the early evaluation of abiraterone and outcome prediction in patients with metastatic castration-resistant prostate cancer (CRPC).

Patient and methods: Forty-three patients with metastatic CRPC progressing after docetaxel received abiraterone 1,000 mg daily with prednisone 5 mg twice daily. Patients were evaluated monthly for serological PSA response and safety. FCH-PET/CT was done at baseline and after 3 to 6 weeks. Univariate and multivariate Cox regression models addressed potential predictors of progression-free survival (PFS) and overall survival (OS).

Results: Declines in PSA level of ≥50% were seen in 21 of 43 (49%) patients. Forty-two patients were evaluable for FCH-PET/CT response. FCH-PET/CT bone flare was observed in 4 of 42 (10%) evaluable patients. In univariate analysis, PSA decline and FCH-PET/CT response predicted PFS, while PSA decline and FCH-PET/CT (progression vs non progression) predicted OS. In multivariate analysis, only FCH-PET/CT (progression vs nonprogression) remained significant for PFS and OS (p = 0.022 and p = 0.027, respectively).

Conclusion: Early FCH-PET/CT can predict clinical outcome in CRPC beyond PSA response. These data support further studies on FCH-PET/CT for abiraterone monitoring and outcome prediction in patients with CRPC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2558

Publication Alerts

Clinical Research Papers:

Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone

Abstract